Evidence map›Paper›PMID 37754795›Full record

ArticleJournal of cardiovascular development and disease2023

Hemoadsorption Using CytoSorb

Cristina Rao, Franziska Preissing, Matthias Thielmann, Daniel Wendt, Zaki Haidari, Jurij Matija Kalisnik, Lothar Daake, Karl Traeger

Open access · goldAbstract read
In one paragraph

Article in Journal of cardiovascular development and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Haemoadsorption in infective endocarditis: a systematic review.Indian journal of thoracic and cardiovascular surgery · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Cristina RaoCytoSorbents Europe, 12587 Berlin, Germany.ORCID 0000-0003-0711-7888
Franziska PreissingCytoSorbents Europe, 12587 Berlin, Germany.
Matthias ThielmannDepartment of Thoracic and Cardiovascular Surgery, West-German Heart & Vascular Center, 45122 Essen, Germany.ORCID 0000-0002-1007-2871
Daniel WendtCytoSorbents Europe, 12587 Berlin, Germany.
Zaki HaidariDepartment of Thoracic and Cardiovascular Surgery, West-German Heart & Vascular Center, 45122 Essen, Germany.
Jurij Matija KalisnikDepartment of Cardiac Surgery, Klinikum Nürnberg, Paracelsus Medical University, 90419 Nuremberg, Germany.ORCID 0000-0002-2227-4091
Lothar DaakeMedical Controlling Department, University of Essen, 45157 Essen, Germany.
Karl TraegerDepartment of Cardiac Anesthesiology, University Hospital Ulm, 89081 Ulm, Germany.
CytoSorbents (Germany) · DEWest German Heart and Vascular Center Essen · DENuremberg Hospital · DEUniversity Hospital Ulm · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A considerable number of infective endocarditis (IE) patients require cardiac surgery with an increased risk for postoperative sepsis. Intraoperative hemoadsorption may diminish the risk of postoperative hyperinflammation with potential economic implications for intensive care unit (ICU) occupation. The present study aimed to theoretically investigate the budget impact of a reduced length of ICU stay in IE patients treated with intraoperative hemoadsorption in the German healthcare system. Data on ICU occupation were extrapolated from a retrospective study on IE patients treated with hemoadsorption. An Excel-based budget impact model was developed to simulate the patient course over the ICU stay. A base-case scenario without therapy reimbursement and a scenario with full therapy reimbursement were explored. The annual eligible German IE patient population was derived from official German Diagnostic-Related Group (DRG) volume data. One-way deterministic sensitivity analysis and multivariate analysis were performed to evaluate the uncertainty over the model results. The use of intraoperative hemoadsorption resulted in EUR 2298 being saved per patient in the base-case scenario without therapy reimbursement. The savings increased to EUR 3804 per patient in the case of full device-specific reimbursement. Deterministic and probabilistic sensitivity analyses confirmed the robustness of savings, with a probability of savings of 87% and 99% in the base-case and full reimbursement scenario, respectively. Intraoperative hemoadsorption in IE patients might have relevant economic benefits related to reduced ICU stays, resulting in improved resource use. Further evaluations in larger prospective cohorts are warranted.

Indexed as

acute infective endocarditiscardiopulmonary bypass surgerycytosorbeconomic evaluationextracorporeal techniqueshemoadsorption

Identifiers

PMID37754795
PMCPMC10531588
OpenAlexW4386223397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.